In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is presenting Spring 2020 events through online platforms and some of our previously scheduled events are being postponed to a later date. Please check our events listing for the latest information and contact our Customer Service team with any additional questions. For Academy programs and resources about COVID-19, click here.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

Annals

Antimicrobial Therapeutics Reviews (1)

Edited by Edited by Karen Bush (Indiana University Bloomington, Bloomington, Indiana)
Antimicrobial Therapeutics Reviews (1)

Published: December 2010

Volume 1213

Reviews on current topics in the areas of antibiotic therapy and research.
Learn More

A new series of reviews, the inaugural installment of Antimicrobial Therapeutics Reviews will be published in the fall of 2010. Among the topics discussed will be: antibiotic cycling (rotation) to reduce emergence of resistance; antibiotics: past and future medical need and public perception; drug discovery successes and failures; efflux pumps and the possibility for broad-spectrum inhibitors; emergence of Clostridium difficile as a major nosocomial pathogen; immunomodulators as adjuvants for antimicrobial therapy and vaccines; potential impact of rapid diagnostics to direct more targeted therapies, or to affect antimicrobial use; regulatory hurdles for new antibiotics; the interface between veterinary and human antibiotic use; and virtual high throughput screening and structure-based design of anti-bacterials.